Triple Therapy in Type 2 Diabetic Patients

• Status: Unknown status
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The treatment of type 2 diabetes mellitus often requires the use of one or more hypoglycemic agents to reach the adequate glycemic control. The aim of the study is to evaluate the effects of a triple therapy with metformin, pioglitazone and sitagliptin on glycemic variability compared to metformin monotherapy, and compared to a combination of metformin and pioglitazone. To assess glycemic variability a continuous glucose monitoring system will be used.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pavia
• Collaborator: IRCCS Policlinico S. Matteo
• Treatments: Metformin; Pioglitazone; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• type 2 diabetic patients

• naive to therapy

• glycated hemoglobin > 6.5 and < 9.0 %

Exclusion Criteria:

• hepatic and renal diseases

• recent cardiovascular diseases

• previous pancreatitis

• history of cancer